# Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery

> **NCT00669734** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 18 (actual)

## Conditions studied

- Locally Advanced Pancreatic Adenocarcinoma
- Pancreatic Acinar Cell Carcinoma
- Pancreatic Ductal Adenocarcinoma
- Stage III Pancreatic Cancer AJCC v6 and v7
- Stage IV Pancreatic Cancer AJCC v6 and v7

## Interventions

- **BIOLOGICAL:** Falimarev
- **BIOLOGICAL:** Inalimarev
- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Sargramostim

## Key facts

- **NCT ID:** NCT00669734
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2010-02-01
- **Primary completion:** 2021-09-02
- **Final completion:** 2027-04-21
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00669734

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00669734, "Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00669734. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*